Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.

Document Type

Journal Article

Publication Date

2-1-2018

Journal

European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology

Volume

20

Issue

2

Inclusive Pages

359–369

DOI

10.1002/ejhf.937

Keywords

Angiotensin-Converting Enzyme Inhibitors; Canada; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Enalapril; Europe; Follow-Up Studies; Heart Failure; Humans; Stroke Volume; Survival Rate; Treatment Outcome; United States

Peer Reviewed

1

This document is currently not available here.

Share

COinS